本帖最后由 老马 于 2012-1-13 21:20 编辑 2 F5 A0 t; I l
( _# b) n* }, K* [( s爱必妥和阿瓦斯丁的比较
) Y z/ D" b" g# c2 S/ W9 c/ h1 B$ B+ \
( I4 x& I1 v& J H# \9 Lhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
+ R( `. U; B' U7 i! G! J7 Y5 a
/ Q9 k5 s$ _! R! V7 \6 U
. v/ [: k: f4 Y8 ]0 W$ V! t# H$ thttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/8 J/ p5 v, [' r) J; K7 ]
==================================================
) _$ k! u6 A* b" j( c# ^2 KOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)1 |- k% p9 D' F m. l8 O
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
; N6 Q/ Z5 B7 y g$ l! fResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
2 d# B v/ B8 N4 R
|